# Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report

## TL;DR

A rare case of a pituitary tumor caused acromegaly-like symptoms despite normal hormone levels, highlighting the need for careful evaluation and treatment.

## Contribution

Reports a rare case of a GH-positive pituitary tumor causing acromegaly-like symptoms with normal GH and IGF-1 levels.

## Key findings

- A 35-year-old woman showed acromegaly-like symptoms with normal GH and IGF-1 levels.
- Surgery reduced IGF-1 and GH levels and partially relieved symptoms and bone metabolism issues.
- The tumor was confirmed as GH and prolactin-positive in histopathology.

## Abstract

Growth hormone (GH) positive pituitary neuroendocrine tumors do not always cause acromegaly. Approximately one-third of GH-positive pituitary tumors are classified as non-functioning pituitary tumors in clinical practice. They typically have GH and serum insulin-like growth factor 1 (IGF-1) levels in the reference range and no acromegaly-like symptoms. However, normal hormone levels might not exclude the underlying hypersecretion of GH. This is a rare and paradoxical case of pituitary tumor causing acromegaly-associated symptoms despite normal GH and IGF-1 levels.

We report a case of a 35-year-old woman with suspicious acromegaly-associated presentations, including facial changes, headache, oligomenorrhea, and new-onset diabetes mellitus and dyslipidemia. Imaging found a 19 × 12 × 8 mm pituitary tumor, but her serum IGF-1 was within the reference, and nadir GH was 0.7ng/ml after glucose load at diagnosis. A thickened skull base, increased uptake in cranial bones in bone scan, and elevated bone turnover markers indicated abnormal bone metabolism. We considered the pituitary tumor, possibly a rare subtype in subtle or clinically silent GH pituitary tumor, likely contributed to her discomforts. After the transsphenoidal surgery, the IGF-1 and nadir GH decreased immediately. A GH and prolactin-positive pituitary neuroendocrine tumor was confirmed in the histopathologic study. No tumor remnant was observed three months after the operation, and her discomforts, glucose, and bone metabolism were partially relieved.

GH-positive pituitary neuroendocrine tumors with hormonal tests that do not meet the diagnostic criteria for acromegaly may also cause GH hypersecretion presentations. Patients with pituitary tumors and suspicious acromegaly symptoms may require more proactive treatment than non-functioning tumors of similar size and invasiveness.

The online version contains supplementary material available at 10.1186/s12902-024-01657-7.